Kim Forest Enterprise Co Ltd

Kim Forest Enterprise Co Ltd exhibits a debt-to-equity ratio of 0.78, indicating a moderate reliance on debt financing. The company's current ratio of 1.23 suggests it has sufficient short-term assets to cover its short-term liabilities, though the liquidity risk is assessed as medium. The negative operating cash flow of -57,167,000 TWD and free cash flow of -138,237,000 TWD highlight ongoing cash outflows, which could constrain its ability to fund operations and capital expenditures without external financing. Profitability metrics are concerning, with a return on equity of -29.84% and a return on assets of -14.39%. These figures indicate that the company is not generating returns that exceed its cost of capital, and its performance is below the typical expectations for the Biotechnology & Medical Research industry. The operating loss of -142,438,000 TWD and net loss of -146,450,000 TWD further underscore the company's financial challenges. The company operates through two segments: Biomedical Experiment Products and Biotechnology and Genetic Testing. The Biomedical Experiment Products segment focuses on laboratory equipment, reagents, and maintenance services, while the Biotechnology and Genetic Testing segment provides sequencing and analysis services. However, the input data does not provide specific revenue breakdowns by segment or geographic region, making it difficult to assess revenue concentration or geographic exposure. The company's growth trajectory is uncertain, as the input data does not include forward-looking revenue projections or historical growth rates. The negative operating and net income figures suggest that the company is not currently expanding profitably. Without clear evidence of revenue growth or margin improvement, the company's ability to sustain operations and invest in future growth is questionable. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's negative net cash position after subtracting total debt is a key flag, suggesting potential challenges in maintaining liquidity. The dilution risk is assessed as low, indicating that the company is not expected to issue additional shares in the near term to raise capital. Recent events and filings are not detailed in the input data, so there is no information available on recent corporate actions, earnings calls, or regulatory developments that could impact the company's operations or financial position. The absence of such information limits the ability to assess the company's strategic direction and response to market conditions.